Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVXL Anavex Life Sciences	$8.22 +0.2%	$8.41	$3.51 ▼ $14.44	$701.76M	0.68	1.21 million shs	308,135 shs
EDIT Editas Medicine	$2.18 +7.4%	$1.54	$0.91 ▼ $6.07	$182.49M	2.1	2.58 million shs	3.19 million shs
ORIC ORIC Pharmaceuticals	$9.67 +3.0%	$6.04	$3.90 ▼ $14.67	$687.42M	1.49	773,618 shs	814,754 shs
XNCR Xencor	$9.43 -0.9%	$9.03	$7.16 ▼ $27.24	$677.55M	0.87	667,127 shs	451,862 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVXL Anavex Life Sciences	+0.24%	+5.66%	+1.23%	-12.83%	+119.20%
EDIT Editas Medicine	+7.39%	+21.11%	+45.33%	+49.32%	-63.91%
ORIC ORIC Pharmaceuticals	+2.98%	+5.57%	+82.11%	+24.13%	+22.41%
XNCR Xencor	-0.95%	+3.40%	+16.28%	-26.10%	-57.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVXL Anavex Life Sciences	3.9304 of 5 stars	3.7	0.0	4.7	3.6	0.8	0.6
EDIT Editas Medicine	4.2821 of 5 stars	3.1	2.0	4.2	2.9	2.5	1.3
ORIC ORIC Pharmaceuticals	3.9106 of 5 stars	3.5	0.0	4.3	2.6	2.5	0.6
XNCR Xencor	4.1928 of 5 stars	3.4	2.0	3.9	3.4	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVXL Anavex Life Sciences	3.33	Buy	$44.00	435.28% Upside
EDIT Editas Medicine	2.29	Hold	$5.36	146.04% Upside
ORIC ORIC Pharmaceuticals	3.00	Buy	$19.17	98.21% Upside
XNCR Xencor	2.89	Moderate Buy	$29.50	212.83% Upside

Current Analyst Ratings Breakdown

Latest EDIT, AVXL, XNCR, and ORIC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	ORIC ORIC Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$20.00
5/13/2025	EDIT Editas Medicine	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $4.00
5/8/2025	XNCR Xencor	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$22.00 ➝ $6.00
5/6/2025	ORIC ORIC Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $12.00
5/6/2025	ORIC ORIC Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/5/2025	ORIC ORIC Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00 ➝ $21.00
4/30/2025	XNCR Xencor	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$31.00
4/29/2025	EDIT Editas Medicine	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
4/28/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$3.00
4/28/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$3.00
4/21/2025	XNCR Xencor	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform

(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.42 per share	N/A
EDIT Editas Medicine	$35.84M	5.09	N/A	N/A	$4.27 per share	0.51
ORIC ORIC Pharmaceuticals	N/A	N/A	N/A	N/A	$3.42 per share	N/A
XNCR Xencor	$127.23M	5.28	N/A	N/A	$10.99 per share	0.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVXL Anavex Life Sciences	-$43M	-$0.55	N/A	N/A	N/A	N/A	-37.50%	-34.08%	8/5/2025 (Estimated)
EDIT Editas Medicine	-$153.22M	-$3.04	N/A	N/A	N/A	-340.96%	-80.13%	-50.99%	8/6/2025 (Estimated)
ORIC ORIC Pharmaceuticals	-$100.70M	-$1.87	N/A	N/A	N/A	N/A	-44.54%	-40.72%	8/11/2025 (Estimated)
XNCR Xencor	-$126.09M	-$3.06	N/A	N/A	N/A	-232.77%	-30.92%	-21.74%	8/4/2025 (Estimated)

Latest EDIT, AVXL, XNCR, and ORIC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q2 2025	AVXL Anavex Life Sciences	-$0.16	-$0.13	+$0.03	-$0.13	N/A	N/A
5/12/2025	Q1 2025	EDIT Editas Medicine	-$0.51	-$0.43	+$0.08	-$0.92	$0.79 million	$4.66 million
5/8/2025	Q1 2025	XNCR Xencor	-$0.60	-$0.66	-$0.06	-$0.66	$23.44 million	$32.73 million
5/5/2025	Q1 2025	ORIC ORIC Pharmaceuticals	-$0.51	-$0.42	+$0.09	-$0.42	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
ORIC ORIC Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVXL Anavex Life Sciences	N/A	9.45	9.45
EDIT Editas Medicine	N/A	3.75	3.75
ORIC ORIC Pharmaceuticals	N/A	10.56	13.15
XNCR Xencor	0.01	6.23	6.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVXL Anavex Life Sciences	31.55%
EDIT Editas Medicine	71.90%
ORIC ORIC Pharmaceuticals	95.05%
XNCR Xencor	N/A

Insider Ownership

Company	Insider Ownership
AVXL Anavex Life Sciences	11.40%
EDIT Editas Medicine	2.10%
ORIC ORIC Pharmaceuticals	6.82%
XNCR Xencor	4.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVXL Anavex Life Sciences	40	85.37 million	75.71 million	Optionable
EDIT Editas Medicine	230	83.71 million	80.98 million	Optionable
ORIC ORIC Pharmaceuticals	80	71.09 million	67.09 million	Optionable
XNCR Xencor	280	71.17 million	66.32 million	Optionable

EDIT, AVXL, XNCR, and ORIC Headlines

Recent News About These Companies

Analysts Set Xencor, Inc. (NASDAQ:XNCR) Target Price at $29.50

June 11 at 3:41 AM | americanbankingnews.com

Xencor (NASDAQ:XNCR) Trading Up 6.3% - Here's What Happened

June 10 at 1:04 PM | marketbeat.com

Bank of America Corp DE Sells 585,930 Shares of Xencor, Inc. (NASDAQ:XNCR)

June 9, 2025 | marketbeat.com

27,491 Shares in Xencor, Inc. (NASDAQ:XNCR) Acquired by Wellington Management Group LLP

June 8, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Moderate Buy" from Brokerages

June 8, 2025 | marketbeat.com

Public Employees Retirement System of Ohio Purchases New Holdings in Xencor, Inc. (NASDAQ:XNCR)

June 3, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Two Sigma Investments LP

May 27, 2025 | marketbeat.com

Nuveen Asset Management LLC Purchases 685,557 Shares of Xencor, Inc. (NASDAQ:XNCR)

May 26, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Holdings Lowered by Jane Street Group LLC

May 26, 2025 | marketbeat.com

Two Sigma Advisers LP Sells 130,900 Shares of Xencor, Inc. (NASDAQ:XNCR)

May 25, 2025 | marketbeat.com

Ameriprise Financial Inc. Has $6.72 Million Stake in Xencor, Inc. (NASDAQ:XNCR)

May 25, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Shares Acquired by RTW Investments LP

May 18, 2025 | marketbeat.com

Point72 Asset Management L.P. Sells 943,148 Shares of Xencor, Inc. (NASDAQ:XNCR)

May 18, 2025 | marketbeat.com

Northern Trust Corp Increases Holdings in Xencor, Inc. (NASDAQ:XNCR)

May 17, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Given Average Recommendation of "Moderate Buy" by Brokerages

May 16, 2025 | marketbeat.com

Jacobs Levy Equity Management Inc. Raises Stock Position in Xencor, Inc. (NASDAQ:XNCR)

May 15, 2025 | marketbeat.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV), Xencor (XNCR) and Intellia Therapeutics (NTLA)

May 13, 2025 | theglobeandmail.com

Leerink Partnrs Has Bearish Forecast for Xencor Q2 Earnings

May 13, 2025 | marketbeat.com

Wedbush Comments on Xencor's Q2 Earnings (NASDAQ:XNCR)

May 13, 2025 | marketbeat.com

Research Analysts Set Expectations for Xencor Q2 Earnings

May 13, 2025 | marketbeat.com

Xencor Reports First Quarter 2025 Financial Results

May 7, 2025 | uk.finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Alphabet Stock Lags—But Waymo May Be Its Hidden Driver
By Gabriel Osorio-Mazilli | May 25, 2025
View Alphabet Stock Lags—But Waymo May Be Its Hidden Driver
Archer Posts Surprise Q1 Beat, Sets Stage for 2025 Revenue Launch
By Jeffrey Neal Johnson | May 14, 2025
View Archer Posts Surprise Q1 Beat, Sets Stage for 2025 Revenue Launch
CRSPR Stock Could Be Ready to Deliver on Its Massive Promise
By Chris Markoch | May 16, 2025
View CRSPR Stock Could Be Ready to Deliver on Its Massive Promise

EDIT, AVXL, XNCR, and ORIC Company Descriptions

Anavex Life Sciences NASDAQ:AVXL

$8.22 +0.02 (+0.24%)

As of 06/12/2025 04:00 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Editas Medicine NASDAQ:EDIT

$2.18 +0.15 (+7.39%)

As of 06/12/2025 04:00 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

ORIC Pharmaceuticals NASDAQ:ORIC

$9.67 +0.28 (+2.98%)

As of 06/12/2025 04:00 PM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Xencor NASDAQ:XNCR

$9.43 -0.09 (-0.95%)

As of 06/12/2025 04:00 PM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time